Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glycotope GmbH - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Glycotope GmbH - Product Pipeline Review - 2015', provides an overview of the Glycotope GmbH's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Glycotope GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Glycotope GmbH including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Glycotope GmbH's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Glycotope GmbH's pipeline products Reasons to buy - Evaluate Glycotope GmbH's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Glycotope GmbH in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Glycotope GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Glycotope GmbH and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Glycotope GmbH - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Glycotope GmbH and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Glycotope GmbH Snapshot 5 Glycotope GmbH Overview 5 Key Information 5 Key Facts 5 Glycotope GmbH - Research and Development Overview 6 Key Therapeutic Areas 6 Glycotope GmbH - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Glycotope GmbH - Pipeline Products Glance 13 Glycotope GmbH - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Glycotope GmbH - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Glycotope GmbH - Drug Profiles 16 cetuximab biobetter 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 FSH-GEX 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 PankoMab-GEX 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 trastuzumab biobetter 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 FVII-GEX 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 GatoMab-GEX 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Seelomab-GEX 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Glycotope GmbH - Pipeline Analysis 25 Glycotope GmbH - Pipeline Products by Target 25 Glycotope GmbH - Pipeline Products by Route of Administration 26 Glycotope GmbH - Pipeline Products by Molecule Type 27 Glycotope GmbH - Pipeline Products by Mechanism of Action 28 Glycotope GmbH - Recent Pipeline Updates 29 Glycotope GmbH - Dormant Projects 32 Glycotope GmbH - Dormant Projects 32 Glycotope GmbH - Locations And Subsidiaries 33 Head Office 33 Other Locations & Subsidiaries 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35
List of Tables
Glycotope GmbH, Key Information 5 Glycotope GmbH, Key Facts 5 Glycotope GmbH - Pipeline by Indication, 2015 8 Glycotope GmbH - Pipeline by Stage of Development, 2015 9 Glycotope GmbH - Monotherapy Products in Pipeline, 2015 10 Glycotope GmbH - Partnered Products in Pipeline, 2015 11 Glycotope GmbH - Partnered Products/ Combination Treatment Modalities, 2015 12 Glycotope GmbH - Phase II, 2015 13 Glycotope GmbH - Phase I, 2015 14 Glycotope GmbH - Preclinical, 2015 15 Glycotope GmbH - Pipeline by Target, 2015 25 Glycotope GmbH - Pipeline by Route of Administration, 2015 26 Glycotope GmbH - Pipeline by Molecule Type, 2015 27 Glycotope GmbH - Pipeline Products by Mechanism of Action, 2015 28 Glycotope GmbH - Recent Pipeline Updates, 2015 29 Glycotope GmbH - Dormant Developmental Projects,2015 32 Glycotope GmbH, Subsidiaries 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.